scholarly journals Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways

2020 ◽  
Vol 16 (7) ◽  
pp. 1121-1134 ◽  
Author(s):  
Xinxing Lu ◽  
Feiya Yang ◽  
Dexi Chen ◽  
Qinxin Zhao ◽  
Dong Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Signaling Pathways ◽  
Akt Signaling ◽  
Docetaxel Resistance

scholarly journals Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer

2019 ◽  
Vol 20 (9) ◽  
pp. 2066 ◽  
Author(s):  
Namrata Khurana ◽  
Suresh C. Sikka
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Signaling Pathways ◽  
Critical Role ◽  
Castration Resistant Prostate Cancer ◽  
Form Complex ◽  
Androgen Receptor Signaling ◽  
Castration Resistant ◽  
Signaling Axis

Androgen receptor (AR) signaling plays a key role not only in the initiation of prostate cancer (PCa) but also in its transition to aggressive and invasive castration-resistant prostate cancer (CRPC). However, the crosstalk of AR with other signaling pathways contributes significantly to the emergence and growth of CRPC. Wnt/β-catenin signaling facilitates ductal morphogenesis in fetal prostate and its anomalous expression has been linked with PCa. β-catenin has also been reported to form complex with AR and thus augment AR signaling in PCa. The transcription factor SOX9 has been shown to be the driving force of aggressive and invasive PCa cells and regulate AR expression in PCa cells. Furthermore, SOX9 has also been shown to propel PCa by the reactivation of Wnt/β-catenin signaling. In this review, we discuss the critical role of SOX9/AR/Wnt/β-catenin signaling axis in the development and progression of CRPC. The phytochemicals like sulforaphane and curcumin that can concurrently target SOX9, AR and Wnt/β-catenin signaling pathways in PCa may thus be beneficial in the chemoprevention of PCa.

MP24-06 INTERACTION BETWEEN DOCETAXEL RESISTANCE AND CASTRATION RESISTANCE IN PROSTATE CANCER: IMPLICATIONS OF TWIST1, YB-1 AND ANDROGEN RECEPTOR

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Masaki Shiota ◽  
Eiji Kashiwagi ◽  
Akira Yokomizo ◽  
Ario Takeuchi ◽  
Takeshi Dejima ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Castration Resistance ◽  
Docetaxel Resistance

scholarly journals Androgen Receptor and ETS-Like Protein-1 Expression of Prostate Cancer Correlates with Gleason Score International Society of Urological Pathology 2014/WHO 2016

2021 ◽  
Vol 9 (A) ◽  
pp. 711-715
Author(s):  
Anandia Putriyuni ◽  
Djong Tjong ◽  
Yanwirasti Yanwirasti ◽  
Ariana Alvarino ◽  
Tofrizal Tofrizal
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Signaling Pathways ◽  
Gleason Score ◽  
International Society ◽  
Significant Prognostic Factor ◽  
Grade Group ◽  
Who Grade ◽  
Who Grade Group ◽  
Histopathological Grading

AIM: Prostate cancer is the second most common and the fifth leading cause of death by cancer in men worldwide now. Grading based on Gleason score is a significant prognostic factor of prostate cancer. Androgen receptor (AR) plays important role in the initiation and progression of prostate cancer. AR signaling pathways in prostate cancer can also promote MAPK/ERK signaling pathways which activate ETS-like protein1 (Elk-1). METHODS: A total of 56 slides and paraffin blocks sampling of prostate cancer by consecutive from Department of Anatomical Pathology in West Sumatera. Hematoxylin and eosin (HE) stained slides were evaluated to review Gleason score, histopathological grading, and WHO grade group based on International Society of Urological Pathology (ISUP) 2014/WHO 2016. Immunohistochemistry staining of AR and Elk-1 was performed to analyze protein expression. RESULTS: Prostate cancers were found in mean age 70.68 ± 7.99 years. The most proportion of prostate cancer was Gleason score 9 (44.64%), histopathological grading poorly differentiated/undifferentiated (76.78%), and WHO grade Group 5 (48.21%). The positive expression AR of tumor cells 39 (69.64%) and Elk-1 34 (60.71%). Statistically, these results showed significant correlations of AR (p = 0.009) and Elk-1 (p = 0.012) with Gleason score. CONCLUSIONS: These results showed complex interactions between AR and Elk-1 initiation and progression of prostate cancer. Both variables indicated a significant correlation with Gleason score so that biomarkers prognostic potentially for prostate cancer.

MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials

2020 ◽  
Vol 13 ◽  
Author(s):  
Safieh Ebrahimi ◽  
Seyed Isaac Hashemy ◽  
Amirhossein Sahebkar ◽  
Seyed Hamid AghaeeBakhtiari
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Signaling Pathways ◽  
Therapeutic Potential ◽  
Splice Variants ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistance ◽  
Contributing Factors ◽  
Development Of Resistance ◽  
Castration Resistant

: Prostate cancer (PCa) is the second most prevalent cancer and the fifth leading cause of cancer-related deaths among men. Androgen deprivation therapy (ADT) is the most frequently used therapeutic strategy in PCa; however, the development of resistance to ADT, known as castration-resistant prostate cancer (CRPC), continues to be a major obstacle against successful treatment of PCa. The abnormal activation of the androgen receptor (AR) signaling pathway has been found as one of the main contributing factors to the development of resistance in CRPC. Therefore, AR regulatory strategies are urgently required to combat resistance. Recently, microRNAs (miRNAs) have been found as major AR regulatory factors affecting ADT resistance. MiRNAs can target AR itself, AR-related genes, AR splice variants, ARrelated signaling pathways as well as cancer stem cells (CSCs), and play critical roles in regulating ADT resistance. Due to their capability to affect various genes and signaling pathways, miRNAs are now being studied for their potential role as a new therapeutic target in CRPC. It has been recommended that combination therapies including miRNAs and existing drugs can synergistically decrease castration resistance. miRNAs have also prognostic values for ADT, and their expression profiling in CRPC patients before therapeutic scheduling may enable the physician to diagnose patients who are ADT-resistant. Overall, extant evidence obviously supports the predictive and therapeutic potential of miRNAs in CRPC patients. This review summarizes the available information about the microRNA-mediated AR controlling mechanisms involved in ADT resistance.

Sign in / Sign up

Export Citation Format

Share Document